Abstract
Heparin has been reported to antagonize the platelet antiaggregating activity of prostacyclin (PGI2) and prostaglandin D2(PGD2). To investigate whether heparin interferes with PGI2 and/or PGD2 binding to the specific membrane platelet receptors, the number and the affinity of binding sites for tritiated PGI2and PGD2 were determined in 8 healthy subjects (aged 25-32; 4 for PGI2 and 4 for PGD2studies) in the absence and in the presence of heparin. Preliminary aggregation tests indicated that the heparin concentration tested (2 I.U./ml) reduced the antiaggregating activity of PGI2 and PGD2. Heparin,when preincubated with platelet suspension, did not induce any significant change in the number/platelet (bs/plt) and affinity (Kd) of PGI2 and PGD2 binding sites (bs) in comparison to control values (PGI2 high affinity bs: bs/plt=106±12 vs 107±17 - Kd=9.7±3.1 vs 10.0±2.3 nM; PGI2 low affinity bs: bs/ptt=3551±233 vs 3670±465 - Kd=877±125±125 vs 833±104 nM; PGD2 bs: bs/plt-228±14 vs 234±24 - Kd=68±10 vs 73±7 nM; p>0.4 for all the differences). No significant binding modification was also observed when heparin was preincubated with 3H-PGI2 and 3H-PGD2. The present demonstration that heparin does not interfere with PGI2 and PGD2 binding to platelets is consistent with the hypothesis that heparin reduces the antiaggregating effects of PGI2 and PGD2 by directly potentiating platelet aggregation.
| Original language | English |
|---|---|
| Pages (from-to) | 319-328 |
| Number of pages | 10 |
| Journal | Thrombosis Research |
| Volume | 40 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Nov 1 1985 |
Fingerprint
Keywords
- Heparin
- Platelet
- Prostacyclin
- Prostaglandin D2
- Receptor
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Hematology
Cite this
Heparin does not interfere with prostacyclin and prostaglandin D2 binding to platelets. / Fortini, A.; Modesti, P. A.; Abbate, R.; Gensini, G. F.; Neri Serneri, G. G.
In: Thrombosis Research, Vol. 40, No. 3, 01.11.1985, p. 319-328.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Heparin does not interfere with prostacyclin and prostaglandin D2 binding to platelets
AU - Fortini, A.
AU - Modesti, P. A.
AU - Abbate, R.
AU - Gensini, G. F.
AU - Neri Serneri, G. G.
PY - 1985/11/1
Y1 - 1985/11/1
N2 - Heparin has been reported to antagonize the platelet antiaggregating activity of prostacyclin (PGI2) and prostaglandin D2(PGD2). To investigate whether heparin interferes with PGI2 and/or PGD2 binding to the specific membrane platelet receptors, the number and the affinity of binding sites for tritiated PGI2and PGD2 were determined in 8 healthy subjects (aged 25-32; 4 for PGI2 and 4 for PGD2studies) in the absence and in the presence of heparin. Preliminary aggregation tests indicated that the heparin concentration tested (2 I.U./ml) reduced the antiaggregating activity of PGI2 and PGD2. Heparin,when preincubated with platelet suspension, did not induce any significant change in the number/platelet (bs/plt) and affinity (Kd) of PGI2 and PGD2 binding sites (bs) in comparison to control values (PGI2 high affinity bs: bs/plt=106±12 vs 107±17 - Kd=9.7±3.1 vs 10.0±2.3 nM; PGI2 low affinity bs: bs/ptt=3551±233 vs 3670±465 - Kd=877±125±125 vs 833±104 nM; PGD2 bs: bs/plt-228±14 vs 234±24 - Kd=68±10 vs 73±7 nM; p>0.4 for all the differences). No significant binding modification was also observed when heparin was preincubated with 3H-PGI2 and 3H-PGD2. The present demonstration that heparin does not interfere with PGI2 and PGD2 binding to platelets is consistent with the hypothesis that heparin reduces the antiaggregating effects of PGI2 and PGD2 by directly potentiating platelet aggregation.
AB - Heparin has been reported to antagonize the platelet antiaggregating activity of prostacyclin (PGI2) and prostaglandin D2(PGD2). To investigate whether heparin interferes with PGI2 and/or PGD2 binding to the specific membrane platelet receptors, the number and the affinity of binding sites for tritiated PGI2and PGD2 were determined in 8 healthy subjects (aged 25-32; 4 for PGI2 and 4 for PGD2studies) in the absence and in the presence of heparin. Preliminary aggregation tests indicated that the heparin concentration tested (2 I.U./ml) reduced the antiaggregating activity of PGI2 and PGD2. Heparin,when preincubated with platelet suspension, did not induce any significant change in the number/platelet (bs/plt) and affinity (Kd) of PGI2 and PGD2 binding sites (bs) in comparison to control values (PGI2 high affinity bs: bs/plt=106±12 vs 107±17 - Kd=9.7±3.1 vs 10.0±2.3 nM; PGI2 low affinity bs: bs/ptt=3551±233 vs 3670±465 - Kd=877±125±125 vs 833±104 nM; PGD2 bs: bs/plt-228±14 vs 234±24 - Kd=68±10 vs 73±7 nM; p>0.4 for all the differences). No significant binding modification was also observed when heparin was preincubated with 3H-PGI2 and 3H-PGD2. The present demonstration that heparin does not interfere with PGI2 and PGD2 binding to platelets is consistent with the hypothesis that heparin reduces the antiaggregating effects of PGI2 and PGD2 by directly potentiating platelet aggregation.
KW - Heparin
KW - Platelet
KW - Prostacyclin
KW - Prostaglandin D2
KW - Receptor
UR - http://www.scopus.com/inward/record.url?scp=0022348483&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022348483&partnerID=8YFLogxK
U2 - 10.1016/0049-3848(85)90267-1
DO - 10.1016/0049-3848(85)90267-1
M3 - Article
C2 - 3001968
AN - SCOPUS:0022348483
VL - 40
SP - 319
EP - 328
JO - Thrombosis Research
JF - Thrombosis Research
SN - 0049-3848
IS - 3
ER -